Fig. 2: Summary of cardiovascular adverse drug reactions associated with agents used to treat MM in Europe and occurring in at least 1 in 1000 patients (all AEs listed with frequency information in the relevant European SmPCs are depicted). | Blood Cancer Journal

Fig. 2: Summary of cardiovascular adverse drug reactions associated with agents used to treat MM in Europe and occurring in at least 1 in 1000 patients (all AEs listed with frequency information in the relevant European SmPCs are depicted).

From: Management of cardiovascular risk in patients with multiple myeloma

Fig. 2: Summary of cardiovascular adverse drug reactions associated with agents used to treat MM in Europe and occurring in at least 1 in 1000 patients (all AEs listed with frequency information in the relevant European SmPCs are depicted).The alternative text for this image may have been generated using AI.

ADR, adverse drug reaction; ECG, electrocardiography; MM, multiple myeloma; PEG, polyethylene glycol; SmPC, summary of product characteristics

Back to article page